Trial Profile
An Evaluation of the Pharmacokinetics and Safety of Fixed and Escalating Doses of Oral Treprostinil Diethanolamine (UT-15C) Sustained Release Tablets in Patients With Systemic Sclerosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jun 2014
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Acronyms DISTOL-PK
- Sponsors United Therapeutics Corporation
- 25 Jun 2014 New trial record
- 13 Jan 2011